A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Latest Information Update: 25 Jul 2024
At a glance
- Drugs MB-106 (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Mustang Bio
- 22 Jul 2024 Status changed from recruiting to discontinued. (Business reasons.)
- 12 Dec 2023 According to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, dosing is ongoing in the final dosing level (1.0x107 cells/kg) to establish the recommended Phase 2 dose for a planned pivotal trial in WM. It is anticipated that the complete data set from the Phase 1 indolent NHL arm will be presented.
- 12 Dec 2023 Results of phase 1 assessing efficacy and safety profile of MB-106 , presented at the 65th American Society of Hematology Annual Meeting and Exposition.